Medtronic (MDT)
94.22
+0.63 (0.67%)
NYSE · Last Trade: Sep 28th, 5:57 AM EDT
Detailed Quote
Previous Close | 93.59 |
---|---|
Open | 93.85 |
Bid | 94.25 |
Ask | 94.50 |
Day's Range | 93.48 - 94.73 |
52 Week Range | 79.29 - 96.25 |
Volume | 5,057,881 |
Market Cap | 126.62B |
PE Ratio (TTM) | 25.96 |
EPS (TTM) | 3.6 |
Dividend & Yield | 2.840 (3.01%) |
1 Month Average Volume | 7,237,382 |
Chart
About Medtronic (MDT)
Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
News & Press Releases
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
Via Benzinga · September 25, 2025
Surgical technology is advancing quickly, and robots are the future, which is why you'll want to look at this high-yield surgical robot maker.
Via The Motley Fool · September 25, 2025
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on the burgeoning market for weight-loss and diabetes drugs, driven by its groundbreaking GLP-1 agonists. In stark contrast, Johnson & Johnson (NYSE:
Via MarketMinute · September 22, 2025
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its
Via MarketMinute · September 22, 2025
Medtronic is one of the largest medical device makers in the world, and it is focused on getting more profitable.
Via The Motley Fool · September 22, 2025
Medtronic's Altaviva wins FDA approval as a minimally invasive implant for urge urinary incontinence, offering long-lasting and low-maintenance therapy.
Via Benzinga · September 19, 2025
In a financial landscape increasingly dominated by the exhilarating, often volatile, narrative of artificial intelligence, Intuitive Surgical (NASDAQ: ISRG) stands as a testament to steady, fundamental innovation. As the market's gaze fixates on every whisper of AI advancement, the pioneer of robotic-assisted surgery continues its work, quietly refining its formidable
Via MarketMinute · September 18, 2025
Sunnyvale, CA – September 17, 2025 – Intuitive Surgical (NASDAQ: ISRG), the pioneer and global leader in robotic-assisted surgery, has once again demonstrated its formidable market position with a robust second-quarter 2025 earnings report. The company announced an impressive adjusted Earnings Per Share (EPS) of $2.19, significantly surpassing analyst expectations, coupled
Via MarketMinute · September 17, 2025
The storied medical device specialist always seems to post encouraging growth.
Via The Motley Fool · September 17, 2025
Via Benzinga · September 17, 2025
Find out how the company's da Vinci surgical robots could remain the preferred option for decades.
Via The Motley Fool · September 16, 2025
Medtronic (MDT) offers a strong 3.01% dividend yield, a history of reliable payouts, and solid profitability, making it a top candidate for sustainable income investors.
Via Chartmill · September 15, 2025
An unbeatable advantage makes this stock a popular one among billionaire investors.
Via The Motley Fool · September 14, 2025
They have increased their payouts for a combined 111 straight years.
Via The Motley Fool · September 13, 2025
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this
Via MarketMinute · September 12, 2025
Medtronic plc is a global medical device manufacturer with leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management, and other medical markets.
Via Talk Markets · September 12, 2025
These robotics leaders are positioned to capitalize as AI transforms machines from tools into intelligent partners.
Via The Motley Fool · September 11, 2025
The market may be overlooking these companies' long-term potential.
Via The Motley Fool · September 7, 2025
MDT stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout setup with a clear risk-reward entry point.
Via Chartmill · September 6, 2025
These income stocks offer above-average yields, have strong fundamentals, and should offer investors a lot of stability over the long run.
Via The Motley Fool · September 5, 2025
Medtronic's Hugo robotic-assisted surgery system showed strong safety and effectiveness in a U.S. hernia repair study, meeting all key clinical goals.
Via Benzinga · September 5, 2025
NEW HOPE, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced new data from its AVIM therapy program, presented at the HRX Live 2025 Meeting, in Atlanta, GA, demonstrating that the blood pressure-lowering effects of AVIM therapy may be sustained for years after activation, are reversible with no evidence of rebound hypertension or blood pressure exceeding initial baseline values, and can be restored upon reactivation. These data further support AVIM therapy’s potential role as a controllable, programmable, and durable device-based therapy for uncontrolled hypertension.
By Orchestra BioMed Holdings, Inc. · Via GlobeNewswire · September 4, 2025